・At Science Day, Moderna outlined growth plans across infectious-disease vaccines, Intismeran, and rare-disease therapeutics. ・CEO Stephane Bancel said Moderna is working to “invent the future,” with ...

Add Yahoo as a preferred source to see more of our stories on Google. new-breakthroughs-in-auto-immune-disease-treatment Canva Scientists are developing revolutionary treatments for autoimmune ...

Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to acquire rare disease drugmaker IntraBio. | Novartis bought an mRNA-coded ...

The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones ...

Newswise — In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including ...

In a new study, scientists from Johns Hopkins Medicine report that an experimental mRNA-based platform has the potential to help deliver next-generation mRNA therapeutics, including vaccines fighting ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and other devastating autoimmune diseases — by reprogramming patients’ out-of-whack immune ...

More than 13 billion doses of mRNA vaccines have been administered globally since the rollout in the United States of COVID-19 shots in December 2020 via Operation Warp Speed under the first Trump ...

Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...